Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

Core Insights - Tevogen Bio has appointed David E. Banko as Global Head of Government Affairs and Patient Access, bringing over 30 years of experience in market access and health policy [1][2][3] - Mr. Banko will focus on advancing patient access to Tevogen's therapies, engaging with payers, and ensuring Health Technology Assessment readiness, which are critical for the company's commercialization strategies [2][4] - Tevogen Bio is a clinical-stage specialty immunotherapy company developing precision T cell therapies for infectious diseases and cancers, with a strong emphasis on patient accessibility and innovative business models [5][6][7] Company Strategy - The appointment of Mr. Banko is seen as a significant step towards commercialization readiness, emphasizing the need for defined value propositions for various stakeholders in the healthcare ecosystem [4] - Tevogen Bio aims to secure appropriate coding, coverage, and reimbursement for its therapies at launch, which is essential for market access [2][4] - The company has reported positive safety data from its proof-of-concept clinical trials and holds key intellectual property assets, including three granted patents and several pending patents related to artificial intelligence [6] Leadership and Expertise - Mr. Banko's previous roles include positions at Cordis Corp and B. Braun Medical Inc., where he successfully enhanced market access for innovative technologies [3] - Tevogen Bio's leadership team consists of experienced industry leaders and scientists focused on drug development and global product launch [7] - The company believes that accessible personalized therapeutics represent the next frontier of medicine, necessitating disruptive business models to sustain innovation [7]